Interestingly, these mitochondrial markers also showed predictive value in ER(−) breast cancer patients, both basal and HER2(+), suggesting that anti-mitochondrial therapy could be used as a more general anti-cancer strategy, against several different breast cancer sub-types. The gene discussed is ERBB2; the disease is breast carcinoma.